Emerging innovations in nanomedicine for cancer immunotherapy

被引：0
作者：
Shah, Jaimin R. [1 ,2 ,3 ]
Kapoor, Devesh U. [4 ]
Prajapati, Bhupendra G. [1 ,5 ,6 ]
机构：
[1] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92037 USA
[2] Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA
[3] Univ Calif San Diego, Program Mat Sci & Engn, La Jolla, CA 92093 USA
[4] Dr Dayaram Patel Pharm Coll, Bardoli 394601, Gujarat, India
[5] Ganpat Univ, Shree SK Patel Coll Pharmaceut Educ & Res, Kherva 384012, Gujarat, India
[6] Silpakorn Univ, Fac Pharm, Nakhon Pathom 73000, Nakhon Pathom P, Thailand
来源：
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY | 2025年 / 104卷
关键词：
Nanomedicine; Tumor microenvironment; Immunotherapy; Gene therapy; Tumor specific antigen; PEGYLATED LIPOSOMAL DOXORUBICIN; TUMOR MICROENVIRONMENT; DENDRITIC CELLS; SOLID TUMORS; PHASE-I; NANOPARTICLES; CHALLENGES; DELIVERY; SIRNA; OPPORTUNITIES;
D O I：
10.1016/j.jddst.2024.106584
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Cancer is characterized by a highly intricate pathophysiology and stands as a chief cause of mortality and illness globally. Traditional treatments for cancer such as chemotherapy, targeted & radiation therapy, and immunotherapy. Despite their widespread use, these therapies have significant limitations. They often suffer from a lack of selectivity, resulting in non-targeted cytotoxic effects that harm healthy tissues. Moreover, these treatments frequently encounter challenges such as inadequate drug delivery to sites of tumor and the development of multidrug resistance, which collectively diminish their overall effectiveness and potency in combating cancer. Nanoparticles (NPs) are increasingly employed as a nanomedicine platform in cancer immunotherapy, thanks to their exceptional physicochemical characteristics, such as size, shape, and surface attributes. This manuscript explores the challenges posed by the tumor microenvironment (TME) in cancer treatment and presents innovative strategies utilizing nanomaterials-based formulations. The resistance of the TME, particularly its physical and immunosuppressive barriers, impedes the efficacy of conventional therapies. We discuss the pharmacodynamics and pharmacokinetics of nanomaterials within the TME, highlighting their role in modifying cancerimmunity phenotypes. The regulation of the TME is critical, with a focus on modulating tumor blood vessels and extravascular components to enhance therapeutic outcomes. Additionally, the manuscript delves into the potential of nanomaterials-based immunotherapy, which can trigger the tumor-specific antigens release, facilitate their presentation, and prime T cells for effective anti-tumor responses. The integration of nanomaterialsbased delivery systems in combination immunotherapy is also explored, showcasing the synergy between nanomedicine and other therapeutic modalities, such as chemotherapy and gene therapy. This comprehensive review underscores the promise of nanomaterials in redefining cancer treatment by overcoming TME-associated resistance and improving immunotherapeutic efficacy.
引用
收藏
页数：14
相关论文
共 155 条
  • [11] Waldman A.D., Fritz J.M., Lenardo M.J., A guide to cancer immunotherapy: from T cell basic science to clinical practice, Nat. Rev. Immunol., 20, 11, pp. 651-668, (2020)
  • [12] Nie Y., Li D., Peng Y., Wang S., Hu S., Liu M., Et al., Metal organic framework coated MnO(2) nanosheets delivering doxorubicin and self-activated DNAzyme for chemo-gene combinatorial treatment of cancer, Int. J. Pharm., 585, (2020)
  • [13] Dai J., Ashrafizadeh M., Aref A.R., Sethi G., Ertas Y.N., Peptide-functionalized, -assembled and -loaded nanoparticles in cancer therapy, Drug Discov. Today, 29, 7, (2024)
  • [14] Wang Y., Xu Y., Song J., Liu X., Liu S., Yang N., Et al., Tumor cell-targeting and tumor microenvironment-responsive nanoplatforms for the multimodal imaging-guided photodynamic/photothermal/chemodynamic treatment of cervical cancer, Int. J. Nanomed., 19, pp. 5837-5858, (2024)
  • [15] Dong X., Liang J., Yang A., Qian Z., Kong D., Lv F., Fluorescence imaging guided CpG nanoparticles-loaded IR820-hydrogel for synergistic photothermal immunotherapy, Biomaterials, 209, pp. 111-125, (2019)
  • [16] Lukyanov A.N., Elbayoumi T.A., Chakilam A.R., Torchilin V.P., Tumor-targeted liposomes: doxorubicin-loaded long-circulating liposomes modified with anti-cancer antibody, J. Contr. Release, 100, 1, pp. 135-144, (2004)
  • [17] Murthy S.K., Nanoparticles in modern medicine: state of the art and future challenges, Int. J. Nanomed., 2, 2, pp. 129-141, (2007)
  • [18] Tanaka T., Decuzzi P., Cristofanilli M., Sakamoto J.H., Tasciotti E., Robertson F.M., Et al., Nanotechnology for breast cancer therapy, Biomed. Microdevices, 11, 1, pp. 49-63, (2009)
  • [19] Harari A., Graciotti M., Bassani-Sternberg M., Kandalaft L.E., Antitumour dendritic cell vaccination in a priming and boosting approach, Nat. Rev. Drug Discov., 19, 9, pp. 635-652, (2020)
  • [20] Noguchi M., Arai G., Matsumoto K., Naito S., Moriya F., Suekane S., Et al., Phase I trial of a cancer vaccine consisting of 20 mixed peptides in patients with castration-resistant prostate cancer: dose-related immune boosting and suppression, Cancer Immunol. Immunother., 64, 4, pp. 493-505, (2015)
12345678910